SSA
RYTM icon

Schonfeld Strategic Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Schonfeld Strategic Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-77,983
Closed -$4.93M – 2526
2025
Q2 		$4.93M Buy
77,983
+20,833
+36% +$1.28M 0.03% 568
2025
Q1 		$3.03M Sell
57,150
-2,550
-4% -$141K 0.02% 749
2024
Q4 		$3.34M Buy
59,700
+29,165
+96% +$1.61M 0.02% 628
2024
Q3 		$1.6M Buy
30,535
+19,614
+180% +$940K 0.01% 985
2024
Q2 		$448K Buy
+10,921
New +$436K ﹤0.01% 1532
2023
Q2 		– Sell
-13,311
Closed -$237K – 2447
2023
Q1 		$237K Sell
13,311
-107,378
-89% -$2.7M ﹤0.01% 1468
2022
Q4 		$3.51M Buy
120,689
+71,786
+147% +$1.84M 0.03% 596
2022
Q3 		$1.2M Buy
+48,903
New +$909K 0.01% 1157
2018
Q4 		– Sell
-47,100
Closed -$1.37M – 1216
2018
Q3 		$1.37M Sell
47,100
-48,900
-51% -$1.55M 0.06% 368
2018
Q2 		$3M Buy
+96,000
New +$2.62M 0.16% 207

Other funds holding RYTM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Schonfeld Strategic Advisors's RYTM Position: Q3 2025 in Review

Schonfeld Strategic Advisors sold out of Rhythm Pharmaceuticals (RYTM) in Q3 2025, closing a stake of 77,983 shares — an estimated $4.93M sold.

Schonfeld Strategic Advisors first reported a position in RYTM in Q2 2018 and held it in 10 quarters. The position peaked at $4.93M in Q2 2025. 264 funds tracked by Wall St. Rank hold RYTM as of Q3 2025.

  • Schonfeld Strategic Advisors reported no remaining Rhythm Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 77,983 Rhythm Pharmaceuticals shares in Q3 2025, an estimated $4.93M.
  • Schonfeld Strategic Advisors first reported a position in Rhythm Pharmaceuticals in Q2 2018 and held it in 10 quarters.
  • Schonfeld Strategic Advisors's Rhythm Pharmaceuticals position peaked at $4.93M in Q2 2025.
  • 264 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.